The Acadian variant of Fanconi Syndrome refers to a specific condition characterized by generalized proximal tubular dysfunction from birth, slowly progressive chronic kidney disease and pulmonary interstitial fibrosis. This condition occurs only in Acadians, a founder population in Nova Scotia, Canada. The genetic and molecular basis of this disease is unknown. We carried out whole exome and genome sequencing and found that nine affected individuals were homozygous for the ultra-rare non-coding variant chr8:96046914 T > C; rs575462405, whereas 13 healthy siblings were either heterozygotes or lacked the mutant allele. This variant is located in intron 2 of NDUFAF6 (NM_152416.3; c.298-768 T > C), 37 base pairs upstream from an alternative splicing variant in NDUFAF6 chr8:96046951 A > G; rs74395342 (c.298-731 A > G). NDUFAF6 encodes NADH:ubiquinone oxidoreductase complex assembly factor 6, also known as C8ORF38. We found that rs575462405-either alone or in combination with rs74395342-affects splicing and synthesis of NDUFAF6 isoforms. Affected kidney and lung † These authors contributed equally to the article. showed specific loss of the mitochondria-located NDUFAF6 isoform and ultrastructural characteristics of mitochondrial dysfunction. Accordingly, affected tissues had defects in mitochondrial respiration and complex I biogenesis that were corrected with NDUFAF6 cDNA transfection. Our results demonstrate that the Acadian variant of Fanconi Syndrome results from mitochondrial respiratory chain complex I deficiency. This information may be used in the diagnosis and prevention of this disease in individuals and families of Acadian descent and broadens the spectrum of the clinical presentation of mitochondrial diseases, respiratory chain defects and defects of complex I specifically.
Acadian variant of Fanconi syndrome is caused by mitochondrial respiratory chain complex I deficiency due to a non-coding mutation in complex I assembly factor NDUFAF6 Renal Fanconi Syndrome (RFS) is a rare condition associated with decreased proximal tubular uptake of electrolytes and organic compounds, resulting in metabolic acidosis, aminoaciduria, phosphaturia and uricosuria (1, 2) . RFS may be caused by medications (3), toxins (4) or genetic mutations affecting the function of the proximal tubule (1, 5) . RFS is often caused also by mitochondrial defects because bulk transport in the proximal tubule is highly energy dependent (6) (7) (8) (9) (10) . For many familial RFS cases, the genetic and molecular basis remains unknown. The Acadian variant of Fanconi Syndrome (AVFS) refers to a form of RFS found only in Acadians, a founder population in Nova Scotia, Canada. This specific form of RFS is associated with abnormalities in proximal tubular reabsorption, chronic kidney disease leading to the need for renal replacement therapy and pulmonary fibrosis (11, 12) . In this investigation, we identified a causative non-coding mutation in NADH:ubiquinone oxidoreductase complex assembly factor 6 (NDUFAF6) that leads to aberrant splicing of NDUFAF6 mRNA and loss of the mitochondria-located NDUFAF6 isoform, resulting in NADH:ubiquinone oxidoreductase complex (mitochondrial respiratory chain complex I) deficiency. These findings are in contrast to a previously reported mutation in NDUFAF6 that resulted in loss of both the mitochondrial and cytoplasmic isoforms and causes Leigh syndrome and early death (13) .
Results
AVFS is characterized by proximal tubular dysfunction, slowly progressive chronic kidney disease, pulmonary interstitial fibrosis and autosomal recessive inheritance
Acadian variant of Fanconi Syndrome has been characterized by generalized proximal tubular dysfunction from birth, slowly progressive chronic kidney disease and pulmonary interstitial fibrosis occurring later in life (11, 12) . In this study, all affected individuals presented with genu valgum (a sign of phosphate deficiency due to phosphaturia associated with RFS) before age 10 years (Table 1 ). Due to the historical characterization of affected individuals, all laboratory analyses were not available in each participant. However, when available, all results consistently pointed to a proximal tubular defect with the following characteristics: (a) proximal renal tubular acidosis, (b) the absence of potassium wasting, (c) generalized aminoaciduria, (d) phosphaturia with hypophosphatemia requiring phosphate replacement, (e) hyperuricosuria with hypouricemia, (f) absence of nephrocalcinosis and (g) elevated urinary lactate (Supplementary Material, Table S1 ). Over time, each affected individual developed slowly progressive kidney failure. Renal ultrasound examination was unremarkable. Pathologic findings from kidney biopsies in two individuals yielded similar results. The majority of glomeruli were normocellular. The interstitium showed patchy fibrosis associated with tubular atrophy and focal collections of chronic mononuclear inflammatory cells.
An occasional cystic dilated tubule was present. There was no tubulitis. Affected individuals progressed to end-stage kidney disease between ages 25 and 40 years (Fig. 1A) . One individual died of uremia prior to the onset of renal replacement therapy. Six individuals received a kidney transplant, and three individuals were placed on maintenance dialysis. Individuals affected with AVFS developed symptoms of dyspnea in their third to fifth decades of life. Initial pulmonary function studies revealed a low carbon monoxide diffusing capacity (DLCO) in the presence of a well-preserved forced vital capacity (FVC) and forced expiratory volume at 1 s (FEV1). The DLCO declined gradually over time, leading to respiratory failure (Fig. 1B) . None of the affected individuals received lung transplantation, with all older individuals involved in the study eventually dying from respiratory failure. Lung biopsies and pathologic specimens from autopsies showed pulmonary interstitial fibrosis as the predominant finding. Computerized axial tomographic scans revealed diffuse interstitial fibrosis, emphysema, and in one individual pulmonary microlithiasis. One individual suffered from the premature onset of lung cancer. Table 1 provides a summary of the individual characteristics.
In total, 12 affected individuals from eight families were studied retrospectively (see Fig. 2 ). There were five individuals from one family with six affected individuals (F1), one family with two affected individuals (F4), two cases were from families with two (F2) and one (F3) unaffected siblings, respectively, and three cases were singletons (F5-7). The pedigree structures and expected founder effect in Acadian population suggested that the disease is inherited in an autosomal recessive manner (Fig. 2) .
Homozygosity mapping and genome sequencing identified a candidate intronic variant in a gene encoding NADH:ubiquinone oxidoreductase complex assembly factor, NDUFAF6 We next confirmed the rs3210518 genotypes in all four individuals from Family 1 and genotyped the other nine healthy family members using Sanger sequencing. This analysis confirmed the relevance of the homozygous region in this family, as all affected individuals were homozygous for the minor rs3210518 variant, whereas all healthy individuals were either heterozygotes or lacked the minor allele (homozygous for the major allele). We also genotyped rs3210518 in three other unrelated individuals affected with AVRFS (F4_II.2, F5_II.1 and F6_II.1). We found that one individual (F4_II.2) was homozygous but two individuals (F5_II.1 and F6_II.1) were heterozygous for the minor rs3210518 allele, excluding this variant as causative.
To identify mutations that we may have missed in the first round of exome sequencing (NimbleGen SeqCap EZ Exome v2) and to identify homozygous regions in both affected individuals that were heterozygous for the minor rs3210518 allele, we sequenced all coding exons and 5 0 -and 3 0 -untranslated regions of their corresponding mRNAs (UTRs) in a pool of genomic DNA obtained from three affected individuals from Family 1 (F1_IV.7, F1_IV.19 and F1_V.2) and DNA samples from two affected individuals (F5_II.1 and F6_II.1) who have been found to be heterozygous for rs3210518; (SeqCap EZ Human Exome þUTR library, Illumina HiSeq 1500). Using this approach, we again did not identify any plausible candidate variants. Nevertheless, using homozygosity mapping, we detected in F5_II.1 and a pooled DNA sample recombination events at the centromeric and telomeric ends of their corresponding homozygous regions, which delimited the candidate homozygous region to chr8:94242350-97172487 ( Fig. 3A and B) .
To identify non-coding variants within the candidate region, we sequenced the whole genomes of F5_II.1 and F1_IV.7 at 30X coverage using the Illumina HiSeq X Ten System. Homozygosity mapping further narrowed candidate homozygous region to chr8: 94423201-96206283. From the 322 variants identified within the candidate homozygous region, we searched for those that were either novel or present at frequencies <0.005 in the 1000 Genomes database, dbSNP database and our internal genome database (10 genomes). We found 16 non-coding variants; 11 variants were intronic, 1 downstream, 3 intergenic and one was located in the 5 0 -UTR (Supplementary Material, Table   S2 ). We prioritized the variants according to conservancy (GERP conservation score) (15, 16) and predicted deleteriousness of SNV's (raw and scaled CADD scores) (17) . Using this approach we defined one candidate variant, chr8:96046914 T > C, in the gene NDUFAF6 (Fig. 3C and D Fig. S1 ).
Using Sanger sequencing, we confirmed homozygosity for the chr8:96046914 T > C variant in all 3 affected individuals from Family 1 as well as in the other 6 individuals affected with AVFS; 13 healthy siblings were either heterozygotes or lacked the mutant allele (Fig. 2) . This variant was absent in 13 200 genomes reported in the Kaviar database (18) . Interestingly, it was found once among 104 individuals from a Puerto Rican sample set that was analyzed within the 1000 genome project; (1000 Genomes Browser).
Identified mutation affects splicing and synthesis of NDUFAF6 isoforms NDUFAF6 encodes assembly factor 6 of the NADH dehydrogenase (ubiquinone) complex I (NDUFAF6), also known as C8ORF38. Knockdown of NDUFAF6 reduces the abundance and activity of mitochondrial complex I (19) and a previously reported mutation of NDUFAF6 led to clinical symptoms of respiratory chain deficiency (OMIM 612392) (13, 20) . RFS is caused by generalized proximal tubular dysfunction, often of mitochondrial origin (7, 9, 21) . We therefore considered that mitochondrial dysfunction resulting from complex I deficiency due to alternative splicing of NDUFAF6 mRNA might be responsible for this phenotype.
Three transcript variants of human NDUFAF6 resulting from alternative mRNA splicing have been proposed to exist (20) . Isoform 1 (NM_152416), (v_1), encodes a 38-kDa protein of 333 amino acids (Q330K2-1), V_1. The protein contains a mitochondrial targeting sequence leading to association of this isoform with the matrix face of the inner mitochondrial membrane (20) . Compared to isoform v_1, isoform 2 (AY444560.1), (v_2), has different exons 1 and 2 and encodes for a protein of 281 amino acids that lack the N-terminal mitochondrial targeting sequence (Q330K2-2), V_2. Isoform 3 (BC028166), (v_3), encodes for a protein of 121 amino acids (Q330K2-3), V_3, which is predicted to have the same N-terminal mitochondrial targeting sequence as V_1 and is truncated due to a stop codon, resulting from alternative splicing of the exon 4/intron 4 boundaries and inclusion of a unique exon 5. This NDUFAF6 isoform is predicted to be targeted to mitochondria (20) , though this has not been proven experimentally.
To explore why AVFS predominantly affects the kidney and lung, we looked at NDUFAF6 expression in the Genotype-Tissue Expression, (GTEX) portal (http://www.gtexportal.org/home/) (22) . NDUFAF6 is ubiquitously expressed in all tissues with lower expression in kidney and lung compared to heart, brain or skeletal muscle. The splicing pattern is more complex than previously reported.
To assess the effect of the c.298-768 T > C mutation on NDUFAF6 mRNA expression, splicing and stability, we isolated total RNA from a participant's skin fibroblasts and autoptic lung tissue and performed reverse transcription polymerase chain reaction (RT-PCR) analyses of the three NDUFAF6 mRNA isoforms. In fibroblasts and lung tissue from affected individuals, we found an altered profile of RT-PCR products (Fig. 4A) . The amounts of RT-PCR products were similar but larger in size than those of control specimens that were obtained from individuals who were either wild-type, heterozygous or homozygous for the c.298-731 A > G splicing SNP. The analysis thus showed that the G nucleotide in this position itself is preferentially used for splicing in the presence of the causative c.298-768 T > C mutation. In both, control and affected samples there were also additional PCR products suggestive of a more complex mRNA splicing pattern. To identify the differences in the splicing pattern of NDUFAF6 in control and affected individuals we isolated and Sanger sequenced major RT-PCR fragments. In parallel we also pair-end sequenced the obtained RT-PCR products using the Illumina HiSeq 1500 system. In addition to the known isoforms v_1, v_2 and v_3 this analysis revealed the existence of several other isoforms. In control samples we identified novel isoforms that we name v_4, v_5, v_6, v_7, v_8, v_9 and v_10 (Supplementary Material, Table S3 ). These isoforms may encode several novel NDUFAF6 isoforms (Supplementary Material, Table S4 ). In affected samples we did not identify isoforms v_1, v_7 and v_8. All other identified cDNA isoforms that we name (v_Nm) had the insertion of 102 nucleotides corresponding to chr8:96046850-96046951 (Fig. 4B, e_mut) . This sequence represents the exonized intronic fragment that contains the c.298-768 T > C mutation and uses the alternative splice donor site created by the chr8:96046951 A > G variant (minor variant of rs74395342). Excluding v_3m and v_5m, the exonized intronic fragment introduces a premature stop codon to identified cDNA variants. This encodes for several classes of truncated NDUFAF6 proteins that either contain the N-terminal mitochondrial targeting sequence or correspond to the truncated N-terminal part of the cytoplasmic isoform V_2. Interestingly all these cDNA isoforms contain the alternative initiation codon beyond the premature stop codon in exon 6. This encodes in all cases for cytoplasmic NDUFAF6 proteins that lack 67 amino acid residues on their N-terminal end compared to the V_2 variant ( Fig. 4B and Supplementary Material, Table S5 ).
To test whether these alternative initiation codons are used for translation, we translated the v_1 and v_2 NDUFAF6 cDNA isoforms in vitro. This analysis revealed the presence of polypeptides of molecular weights corresponding to nascent V_1 and V_2 isoforms (at $38 and 33 kDa) together with polypeptides of isoforms $29 and 26 kDa, theoretically corresponding to cytoplasmic isoforms translated from the alternative initiation codons (Fig. 5A ). This indicates that affected individuals may lose the mitochondrial NDUFAF6 but may have preserved cytoplasmic function by the expression of this truncated cytosolic NDUFAF6 forms.
To assess the effect of the identified splicing mutation on NDUFAF6 expression and intracellular localization we performed Western-blot analysis of affected and control skin fibroblasts along with HeLa and HEK cells transiently expressing recombinant human mitochondrial NDUFAF6 isoform V_1. For Western-blot detection we used three types of commercially available polyclonal antibodies that were raised against different epitopes of NDUFAF6. In agreement with the cDNA analysis and HEK cells transiently expressing recombinant human NDUFAF6 V_1 as well as control and affected skin fibroblasts from F2_II.1. Detection with anti-NDUFAF6 antibody (ab150975) shows a specific increase in the amount of the immune-reactive protein of a molecular weight $33 kDa corresponding to predicted molecular weight of the processed (e.g. with mitochondrial targeting signal removed) NDUFAF6 isoform V_1 in transiently transfected HeLa and HEK cells. Analysis of the cytoplasmic and mitochondrial fractions demonstrates specific presence of the processed NDUFAF6 V_1 isoform in the mitochondria. In the skin fibroblasts, the amounts of NDUFAF6 V_1 isoform are reduced in total homogenate and mitochondrial fraction from F2_II.1 versus control (arrow). The amounts of the immune-reactive proteins of a molecular weight $29 and 26 kDa in the cytoplasmic fraction theoretically corresponding to predicted molecular weights of the cytoplasmic NDUFAF6 isoforms are either comparable or reduced in the proband versus control (dotted and dashed arrows, respectively). Immunodetection of the ATP5B shows efficiency of the cytoplasm/mitochondria fractionation and demonstrate that approximately equal protein amounts have been analyzed in paired samples. (C) Western-blot analysis of NDUFAF6 in control human tissues. Detection with anti-NDUFAF6 antibody (ab151096) shows a decreased amount of NDUFAF6 in lung and kidney compared to heart, skeletal muscle and liver. Volumes of tissue lysates corresponding either to 30 mg of total protein (heart, muscle, liver and kidney) or to 50 mg of total protein (lung) were analyzed. The graphs show the relative amounts of NDUFAF6 compared to heart when normalized either to SDHA (left) or to actin (right). and predicted outcome, this analysis revealed loss of the mitochondrial NDUFAF6 isoform V_1 in affected fibroblasts (at $33 kDa). The amounts of the immune-reactive proteins of a molecular weight $29 and 26 kDa in the cytoplasmic fraction theoretically corresponding to predicted molecular weights of the cytoplasmic NDUFAF6 isoforms were either comparable or reduced in affected individual F2_II.1 (Fig. 5B) . Thus, in the affected individual NDUFAF6 is present in the cytoplasm but not in the mitochondria.
We also performed Western-blot analysis of NDUFAF6 in various control human tissues. In accordance with tissue specific gene expression profiles (see above) there was decreased NDUFAF6 in lung and kidney (41% and 23%, respectively, when normalized to SDHA and compared to heart; and 7% and 47%, respectively, when normalized to actin and compared to heart), (Fig. 5C ), which may explain why the kidney and lung are exclusively affected in this condition.
Affected kidney and lung have altered intracellular distribution of NDUFAF6 and ultrastructural characteristics of mitochondrial dysfunction
To assess effects of the aberrant NDUFAF6 mRNA splicing on expression and intracellular localization of NDUFAF6 isoforms and to evaluate the histopathologic and ultrastructural aspects of this disease, we performed immunohistochemical and immunofluorescence analyses of NDUFAF6 and electron microscopic analysis of kidney and lung from controls and affected individuals (Figs. 6-9 ).
In the controls ( Fig. 6A and B) , there was a distinctive granular pattern and concentration of the NDUFAF6 signal in the basal zone of the proximal tubular cells-a site of maximal concentration of mitochondria. In the kidney biopsy of F1_IV.2 ( Fig. 6C and D) , foci of interstitial and periglomerular fibrosis with small groups of atrophic tubules were detected (Fig. 6C) , and increased desquamation and vacuolar degeneration of proximal tubular cells with frequent protrusions of the plasma membranes was present (Fig. 6D) . Immunohistochemical staining for the NDUFAF6 protein was reduced in the proximal tubules ( Fig. 6C and D) in comparison with controls ( Fig. 6A and  B) . In affected individuals concentration of the NDUFAF6 signal in the basal zone of the proximal tubular cells was not present.
Immunofluorescence detection and colocalization of NDUFAF6 with mitochondrial ATP synthase subunit b (ATPB) and cytoplasmic located heat shock protein 90 (HSP90) (Fig. 7 ) demonstrated in affected kidney absence of NDUFAF6 staining in mitochondria ( Fig. 7G and H) and reduced colocalization signal of NDUFAF6 and HSP90 in the cytoplasm ( Fig. 7O and P) .
Electron microscopic analysis was performed on the kidney biopsy of F1_V.2 ( Fig. 8) . Pathologic changes were expressed with maximal intensity in the proximal tubules. The ultrastructural pattern was dominated by the presence of numerous electron lucent vacuoles in the cytoplasm ( Fig. 8A and B) , microvillous loss and plasma membrane blebbing (Fig. 8B) , mitochondrial structural abnormalities and significant signs of autophagy and mitophagy in particular ( Fig. 8C-E) . Mitochondrial cristae appeared electron dense and thick ( Fig. 8C  and D) . Abnormal configuration or reduction of mitochondrial cristae ( Fig. 8C-E) , intramitochondrial electron dense inclusions ( Fig. S2 ), mitochondrial ATP synthase subunit b (ATP5B) and cytoplasmic located heat shock protein 90 (HSP90) (Fig. 10 ) demonstrated in affected lung the absence of NDUFAF6 staining in mitochondria (Supplementary Material, Figs S2H and L and 10F and I) and reduced colocalization signal of NDUFAF6 and HSP90 in the cytoplasm (Fig. 10O and R) . 
Affected tissues have defects in mitochondrial respiration and complex I biogenesis
To obtain insight into the molecular and functional consequences of the NDUFAF6 mutation we followed complex I biogenesis, the content of respiratory chain enzymes and oxidative phosphorylation (OXPHOS) activity.
First, we checked the steady state levels of representative subunits for complex I and other OXPHOS components on SDS-PAGE (Fig. 11A) . Both in isolated mitochondria from affected lung (F1_IV.19), and whole cells or isolated mitochondria from affected fibroblasts (F2_II.1), we found a profound decrease in the levels of all complex I subunits checked (NDUFA9, NDUFS3 and NDUFB8). Depending on the tissue or particular subunit, the residual content varied between 3% and 63% of control levels when expressed relative to the amount of SDHA. Content of other OXPHOS complexes was either unchanged (complex III, complex V) or displayed slight compensatory increase (complex IV) in fibroblasts. We also performed mass spectrometry labelfree quantification of protein content on affected individual versus control fibroblasts (Fig. 11C) . Altogether we quantified 3249 proteins, with 512 of them classified as mitochondrial in the Mitocarta 2.0 database (23), obtaining coverage of 44% of the mitoproteome. Similarly to the SDS-PAGE, amounts of 23 out of 24 detected complex I subunits were decreased (17/24 significantly) in fibroblasts from an affected individual (F2_II.1). In contrast, other OXPHOS complexes showed tendency towards increase (not shown).
Next we utilized native electrophoretic techniques (Blue native-BN and Clear native-CN PAGE) to study the native organization of OXPHOS complexes in the inner mitochondrial membrane (Fig. 11B) . Using the mild detergent digitonin, we observed most of complex I to be present in several supercomplex forms associated with complex III and complex IV (24) . In both the isolated mitochondria from the lung of an affected individual (F1_IV. 19) , and fibroblasts (whole cells or isolated mitochondria) from another affected individual (F2_II.1), the detected in-gel activity and amount of complex I were significantly lower than in control samples. For detection of complex I we used an NDUFA9 antibody, as NDUFA9 is one of the subunits that incorporates into the early subassemblies of complex I (25). We did not observe any assembly intermediates of complex I, indicating that subcomplexes with stalled assembly are readily degraded. The absence of complex I in affected individuals also led to a profound increase in the amount of free complex III dimer, especially in fibroblast samples, as it was no longer associated into supercomplexes with complex I. This pattern of an isolated complex I defect and subsequent redistribution of complex III between its supercomplex and free forms is remarkably similar to the pattern observed in the previously described case of an NDUFAF6 mutation presenting as Leigh syndrome (20, 26) . Thus, while the cytosolic chaperoning function of NDUFAF6 (26) is likely retained in our probands, for proper complex I assembly both cytosolic and mitochondrial NDUFAF6 is required.
The functional impact of complex I deficiency caused by NDUFAF6 mutation was evaluated by high-resolution respirometry (Fig. 11D) . Oxygen consumption of digitonin-permeabilized fibroblasts was recorded in the presence of saturating concentrations of substrates feeding electrons to the respiratory chain through complex I (pyruvate þ malate þ glutamate) and ADP to achieve state 3 respiration. Under these conditions, the affected individual's fibroblasts (F2_II.1) displayed profound respiratory deficiency, with an almost 4-fold decreased respiratory rate compared to control fibroblasts. The defect was partially alleviated by the addition of succinate, which contributes electrons to the respiratory chain through alternative entry at complex II. Nevertheless, the overall state 3 respiratory rate of an affected individual's fibroblasts in the presence of saturating substrate combination was still significantly decreased by 35% compared to controls (Fig. 11D) . Expressed in relative terms, the oxidation of complex I-dependent substrates accounted for only 28% of the overall state 3 respiration, whereas in controls complex I substrates respiration contributed 74%. Under FCCP-induced uncoupled respiration conditions, where the maximum OXPHOS capacity can be determined, the decreased content of complex I also limited the affected individual's fibroblast respiration by 49% compared to controls (not shown).
Altered mitochondrial respiration and complex I biogenesis of fibroblasts from an affected individual were corrected with NDUFAF6 cDNA transfection
To prove the effect of the NDUFAF6 deficiency on mitochondrial respiration and complex I biogenesis we transiently transfected affected fibroblasts with the wild-type mitochondrial NDUFAF6 isoform v_1 cDNA. At the level of protein content (Fig. 12A) , we observed an increase in the amount of all examined complex I subunits (NDUFA9, NDUFS3 and NDUFB8). Upon NDUFAF6 transfection, their content in affected fibroblasts increased from $3-10% to 30-40% of control levels, expressed relative to SDHA. NDUFAF6 transfection did not change the content of representative complex II (SDHA) and complex III (CORE2) subunits. This increase in the steady state content of complex I subunits was also mirrored by an increase in the signal of fully assembled complex I on native electrophoreses (Fig. 12B) . NDUFAF6 transfection clearly increased in-gel complex I activity and complex I content, with almost all complex I present in supercomplex forms, as observed also in control cells. While complex III content in the supercomplex area was also significantly higher (Fig. 11B, rightmost panel) , there was still a considerable amount of complex III present as free dimer, observed also in affected cells. In agreement with SDS-PAGE, native electrophoresis also showed no changes in complex II content upon transfection, indicating the specificity of NDUFAF6 for complex I assembly. of five independent experiments with control (black) and affected individual (gray) fibroblasts. Rates were calculated from measurements in the presence of 10 mM pyruvate þ 2 mM malate þ 10 mM glutamate þ 1 mM ADP (state 3 CI substrates), or the above þ 10 mM succinate (state 3 CI þ CII substrates); *P < 0.05, ***P < 0.001. This partial restoration of complex I content after transfection of affected fibroblasts with wtNDUFAF6 was sufficient to functionally correct the complex I defect at the level of respiration with complex I-dependent substrates. As shown by the representative oxygen consumption traces (Fig. 12C) , the NDUFAF6-transfected fibroblasts displayed an intermediary phenotype between controls and non-transfected affected cells. Specifically, the NDUFAF6 transfection caused a significant, 2.3-fold increase in state 3 respiration with complex I substrates (Fig. 12D) . While we did not observe full correction of the defect, restoration of complex I dependent respiration was in good agreement with the observed increase in complex I content and both mirrored the average transfection efficiency ($40%) of the electroporation system.
Discussion
In this investigation we identified an intronic mutation in NDUFAF6 as a cause of RFS, chronic kidney failure and progressive pulmonary fibrosis in several families and unrelated Figure 12 . Rescue of the complex I defect by wt NDUFAF6. (A) SDS-PAGE and Western-blot analysis of the fibroblasts from control (C), affected proband (P) and affected proband transfected with wt NDUFAF6 (P þ NDUFAF6). Antibodies specific to NDUFAF6 protein, complex I subunits (NDUFA9, NDUFS3, NDUFB8), complex II subunit SDHA, complex III subunit CORE2 and actin were used. (B) Fibroblasts from control (C), affected proband (P) and affected proband transfected with wt NDUFAF6 (P þ NDUFAF6) were solubilized by digitonin (2 g/g) and analyzed on 4-13% gradient gel using CNE for complex I in-gel activity and BNE for Western blot. Specific monoclonal antibodies were used for detection of complex I (NDUFA9), complex II (SDHA) and complex III (CORE1) native forms. CIII 2 denotes the dimer of complex III; CIII þ CIV denotes the supercomplex of complex III and complex IV and SC's denotes various supercomplexes containing complex I, complex III and complex IV. (C) Oxygen consumption traces of representative complementation experiment with control (black), proband (dark gray) and NDUFA6-transfected affected proband's fibroblasts (light gray). Rates are normalized to protein content. Additions of 0.05 g/g protein of digitonin (DIG), 10 mM pyruvate þ 2 mM malate (P þ M), 1 mM ADP (ADP), 10 mM glutamate (GLU), 10 mM succinate (SUC), 10 mM glycerol 3-phosphate (G3P), 500 nM oligomycin (OMY), FCCP (0-300 nM titration), 500 nM rotenone (ROT) and 10 mM malonate (MAL) are indicated by arrows. (D) Respiratory rates are displayed as mean values of five independent experiments with control (black) and affected proband's (dark gray) fibroblasts, or two independent experiments with NDUFAF6-transfected fibroblasts from affected individual (light gray). Rates were calculated from measurements in the presence of 10 mM pyruvate þ 2 mM malate þ 10 mM glutamate þ 1 mM ADP (state 3 CI substrates), or the above þ 10 mM succinate (state 3 CI þ CII substrates); *P < 0.05. individuals of the Acadian population of eastern Canada. The mutation fully segregates with the phenotype in the expected autosomal recessive mode of inheritance. It is ultra-rare, being present only once in >13 200 genome sequences reported in publicly available databases.
As part of this investigation, we identified several novel mRNA isoforms of NDUFAF6, and we showed that the mutation alters their splicing. From the experiments we performed, we were able to predict and prove that the mutation affects the synthesis and intracellular localization of NDUFAF6 isoforms. This is best demonstrated with the mitochondrial isoform V_1, which was not found in affected tissues based on the results of RT-PCR, cDNA sequencing, Western-blot analyses and immunohistochemical and immunofluorescence studies. These experiments also indicate that the cytosplasmic function of NDUFAF6 (26) may be partially preserved due to the synthesis of truncated NDUFAF6 isoforms that localize in the cytoplasm.
A homozygous mutation in NDUFAF6, c.296A > G, that is predicted to result in Gln99Arg substitution in NDUFAF6 was previously identified in two siblings who suffered from persistent lactic acidosis, Leigh syndrome, isolated generalized complex I deficiency and death before age 3 years (13). This phenotype resulted from altered splicing and instability of the v_1 isoform through a mechanism of nonsense mediated decay, whereas the stability and amounts of the v_3 isoform encoding truncated mitochondrial isoform V_3 was unaffected (20) . In this case, the expected NDUFAF6 deficiency led to reduced levels of the mature complex I in affected fibroblasts, due to loss of the mitochondrial encoded subunit ND1 and disruption of the initial stages of complex I biogenesis. Effects of the mutation on production of the cytoplasmic isoform V_2 were not studied (20) .
We made similar observations in affected fibroblasts and lung from individuals with AVFS. We found a profound decrease in the levels of all complex I subunits that was associated with reduced activity and amount of the mature complex I and an altered pattern of redistribution of complex III between its supercomplex and free forms. This was accompanied by profound respiratory deficiency shown by high-resolution respirometry. All these specific abnormalities were restored when affected fibroblasts were transiently transfected with the cDNA encoding wild-type NDUFAF6 isoform V_1.
We believe that these genetic, molecular biologic, immunohistochemical and biochemical findings firmly established that AVFS is caused by homozygosity for the specific mutation that is composed of the private non-coding mutation c.298-768 T > C (rs575462405) which is in linkage with the population frequent splicing variant c.298-731 A > G (rs74395342). This particular haplotype affects the splicing, synthesis and intracellular distribution of NDUFAF6 isoforms and leads to isolated complex I deficiency.
Fanconi syndrome results from a generalized disturbance in cellular metabolism that affects the primary function of the proximal tubular cell: bulk translocation of electrolytes, organic compounds and macromolecules from the tubular space. As this transport requires a high amount of energy, it is unsurprising that both primary and secondary mitochondrial defects have been identified as causes of the Fanconi syndrome (1, (6) (7) (8) (9) 21, 27, 28) .
Why is it that one mutation (c.296A > G) leads to Leigh syndrome and early death, whereas another mutation (c.298-768 T > C)-or more specifically the haplotype formed by combination of c.298-768 T > C and c.298-731 A > G-leads to specific tubular dysfunction and later in life to chronic kidney failure and pulmonary fibrosis with no other clinical manifestations characteristic of respiratory chain defects such lactic acidosis, cardiomyopathy, myopathy and neurodegeneration?
The explanation might be that in the case of Leigh syndrome the mutation lead to complete loss of both mitochondrial (20) and cytoplasmic NDUFAF6 isoforms while in the case of AVFS some of the identified mutated mRNA (cDNA) isoforms may produce truncated cytoplasmic proteins that can sustain NDUFAF6 cytoplasmic function, as suggested by RT-PCR, in vitro translation, Western blot and immunofluorescence colocalization studies. This would be very similar to investigations with Drosophila melanogaster where the complete loss of Sicily, a homologue of the human NDUFAF6, lead to progressive neurodegeneration and structural mitochondrial abnormalities that are compatible with other forms of severe complex I deficiencies (26) . In that study it was shown that the cytoplasmic form of Sicily interacts with Hsp90 and prevents degradation of cytosolic complex I subunits. Interestingly, and very similar to AVFS, the neurodegenerative phenotype of the Sicily mutants was almost completely rescued by the cytoplasmic form of the Sicily itself, with the exception of the mitochondrial structural abnormalities.
In a similar manner, in AVFS the cytoplasmic NDUFAF6 isoforms may interact with HSP90 (as demonstrated by immunofluorescence studies) and sustain other functions, thereby preventing development of the myopathic and/or neurodegenerative phenotype. On the other hand, the loss of the mitochondrial NDUFAF6 isoforms may lead to partial complex I deficiency and structural mitochondrial defects that may specifically affect systems and tissues with high energy requirements for endocytosis/membrane transport processes, and over time lead to chronic changes that would manifest only in the cell types that have endogenously lower expression of NDUFAF6 and/or that are increasingly sensitive to excessive production of reactive oxygen species (ROS) (e.g. tubular epithelial cells and type I pneumocytes). This is consistent with histopathologic and ultrastructural evaluation of the kidney from an affected individual, which revealed proximal tubulopathy of mitochondrial origin and slowly progressive chronic tubulointerstitial changes. Investigations of affected lung tissue demonstrated distinctive expression of NDUFAF6 in pulmonary epithelial cells that are targeted in idiopathic pulmonary fibrosis. Mitochondrial dysfunction in these cells (29, 30) may disturb the integrity of the alveolar epithelium and provoke hyperplasia of type II pneumocytes and progressive interstitial fibroplasia that are established pathogenetic mechanisms in interstitial pulmonary fibrosis.
In conclusion, we describe a genetically distinct form of Fanconi syndrome. This information may be used in the diagnosis and prevention of this disease in individuals and families of Acadian descent and broadens the spectrum of the clinical presentation of mitochondrial diseases, respiratory chain defects and defects of complex I specifically.
Materials and Methods

Study subjects and clinical examination
An individual affected with proximal renal tubular acidosis (RTA) contacted one of the investigators (AJB) to help identify the genetic cause of this disorder. Further affected individuals were referred by the index case or local nephrologists. After obtaining informed consent, medical records, a blood sample for genetic analysis and other clinical samples were obtained. This investigation was approved by the Wake Forest University School of Medicine, the First Faculty of Medicine of the Charles University, Prague, the Czech Republic and the Moncton Regional Hospital, Moncton, New Brunswick.
Whole exome sequencing
Genomic DNA of all available individuals was extracted from whole blood samples in a standard manner. Whole exome sequencing (WES) was performed using the SOLiD TM 4
(ThermoFisher Scientific, Waltham, MA) and HiSeq 1500 systems (Illumina, San Diego, CA). (35) .
SOLiD 4 sequencing
Illumina sequencing
For DNA enrichment, barcoded DNA libraries and NimbleGen SeqCap EZ Exome v3 (Roche, Madison, WI) were used according to the manufacturer's protocol. DNA sequencing was performed on the captured barcoded DNA library using the Illumina Hiseq 1500 system at the Genomic facility in Motol University Hospital in Prague. The resulting FASTQ files were aligned to the Human Genome Reference (hg19) using Novoalign (3.02.10). Following genome alignment, conversion of SAM format to BAM and duplicate removal were performed using Picard Tools (1.129). The Genome Analysis Toolkit, GATK (3.3) (36) was used for local realignment around indels, base recalibration and variant recalibration and genotyping. Variant annotation were performed with SnpEff (37) and GEMINI (38) . Variants with minor allelic frequencies (MAFs) in ESP6500, ExAC and 1000 Genomes databases <0.05 were further evaluated as described above.
CNV prediction
CNV were identified from exome read counts using CoNIFER (0.2.2) (39).
Homozygosity mapping
Runs of homozygosity (ROHs) were identified from genotyping data using the GEMINI framework and the ROH tool (38) . Allele frequency was calculated and visualized using TTR R-package by smooth moving average (SMA) algorithm, where the moving average was set to 8000 in genome dataset.
Whole genome sequencing (WGS)
DNA libraries were prepared using the TruSeq Nano DNA Library Prep kit (Illumina) and sequenced on the Illumina HiSeq X Ten System (Macrogen, Rockvill, MD). Alignment, variant calling, annotation and copy number analysis were done as described (40) .
Genotyping
All genetic variants of interest were genotyped by direct Sanger sequencing using the version 3.1 Dye Terminator cycle sequencing kit (ThermoFisher Scientific) with electrophoresis on an ABI 3500XL Avant Genetic Analyzer (ThermoFisher Scientific). Data were analyzed using Sequencing Analysis software (ThermoFisher Scientific).
In silico splice site prediction
For prediction of eventual splicing effects of the identified noncoding variants we used Alamut Mutation Interpretation Software (Interactive Biosoftware, Rouen, France).
Cell culture
Skin fibroblasts were maintained in Dulbecco's modified eagle medium (DMEM), (ThermoFisher Scientific), supplemented with 10% fetal bovine serum (FBS), (ThermoFischer Scientific) and penicillin/streptomycin (Sigma-Aldrich, Prague, Czech Republic).
RNA analysis and cDNA sequencing
Total RNA was isolated from fibroblast cell line pellets or snapfrozen lung specimens using TRIzol solution (ThermoFischer Scientific). RNA concentrations were determined spectrophotometrically at A260 nm by NanoDrop (NanoDrop Technologies, Wilmington, DE), and RNA quality was verified using an Agilent 2100 bioanalyser-RNA Lab-On-a-Chip (Agilent Technologies, Santa Clara, CA). Aliquots of isolated RNA were stored at À80 C until analysis. The first-strand cDNA synthesis was carried out using an oligo-dT primer and either SuperScript V R III Reverse Transcriptase or ThermoScript Reverse Transcriptase (ThermoFisher Scientific) or ProtoScript II First Strand cDNA Synthesis Kit (NEB, Ipswich, MA). NDUFAF6 cDNA were PCRamplified from the synthesized first-strand cDNA using oligonucleotide primers (Generi Biotech, Hradec Kr alové , Czech Republic) designed to span and amplify NDUFAF6 isoforms v_1 and v_3 in parallel and isoform v_2 separately. The resultant PCR products were analyzed using agarose gel electrophoresis. Individual DNA fragments were extracted from gel slices using PureLink Quick Gel Extraction Kit (ThermoFisher Scientific) and sequenced using the version 3.1 Dye Terminator cycle sequencing kit (ThermoFisher Scientific) with electrophoresis on an ABI 3500XL Avant Genetic Analyzer (ThermoFisher Scientific). Obtained RT-PCR products were also sequenced in parallel using the Illumina HiSeq 1500 system as described for WES and WGS above. The resulting FASTQ files were aligned to the Human Genome Reference (hg19) using TopHat 2.0.12 (41) integrated in the RAP: RNA-Seq Analysis Pipeline (42).
In vitro translation assay
Wild-type NDUFAF6 isoforms v_1 and v_2 cDNA were synthesized by GenScript (Piscataway, NJ). Protein precursors were synthesized in the presence of 35 S-methionine using TNT T7 Quick Coupled Transcription/Translation System (Promega, Madison, WI) with plasmids as a DNA template, according to manufacturer recommendation. Translation products were centrifuged at 13 000g for 2 min and supernatant was mixed with SDS sample lysis buffer. Samples were analyzed by SDS-PAGE and radioactivity was detected using Pharos system (Bio-Rad Laboratories; Hercules, CA).
Transient transfection and Western-blot analysis of NDUFAF6
Wild-type NDUFAF6 isoform v_1 cDNA was synthesized by GenScript (Piscataway, NJ). HeLa and HEK 293 cells were maintained in DMEM High Glucose medium supplemented with 10% (vol/vol) fetal calf serum (PAA), 100 U/ml penicillin G (SigmaAldrich) and 100 mg/ml streptomycin sulfate (PAA Laboratories GmbH, Pashing, Austria). Transfections were carried out using Lipofectamine 3000 TM (ThermoFischer Scientific) with either 1.5 or 4 mg DNA for 1.5Â10 5 or 8Â10 5 cells, respectively.
Cells were harvested either 24 h (for HeLa and HEK 293 cells) or 5 days (for fibroblasts) post-transfection, and mitochondrial and cytoplasmic fraction were prepared using Mitochondria/ Cytosol Fractionation Kit (BioVision, Inc., San Francisco, CA).
Control human tissue lysates from muscle (Muscle NB820-59253), liver (Liver NB820-59232) and kidney (Kidney NB820-59231) were purchased from Novus Biologicals (Littleton, CO). Lysates from heart and lung were prepared from frozen autopsy tissues. Briefly, frozen tissue was cut out and homogenized in a Teflon/glass homogenizer in RIPA Buffer (150 mM NaCl, 1% Nonidet NP-40, 1% sodium deoxycholate, 0.1% SDS, 50 mM TrisHCl, pH 8.0; 10% homogenate), incubated for 30 min at 37 C and centrifuged for 5 min at 18 000g to remove non-lysed proteins. Denatured protein samples were separated on 13% SDS-PAGE and blotted onto a PVDF membrane. NDUFAF6 was visualized by incubation with rabbit polyclonal antibodies supposedly capable of detecting NDUFAF6 isoforms V_1 and V_2-ab150975 and ab151096 (Abcam, Cambridge) or sc-87001 (Santa Cruz Biotechnology, Heidelberg, Germany), followed by incubation with anti-rabbit IgG-peroxidase antibody-A8924 (Sigma_ Aldrich), and detection by SuperSignal West Pico Maximum Sensitivity Substrate (ThermoFisher Scientific). Succinate dehydrogenase complex, subunit A (SDHA) was visualized using mouse monoclonal antibody ab14715 (Abcam). Actin was visualized using mouse monoclonal anti-Actin (Ab-1) antibody CP01-1EA (Calbiochem, CA).
Immunohistochemistry and immunofluorescence analysis
Formaldehyde fixed kidney and lung samples were analyzed. Immunodetection of NDUFAF6 on paraffin sections was performed using the rabbit polyclonal anti-NDUFAF6 antibody sc-87001 (Santa Cruz Biotechnology) diluted 1:200 in 5% BSA, in PBS. Detection of bound primary antibody was achieved using the Dako EnVision þ TM Peroxidase Rabbit Kit (Dako, Glostrup, Denmark) with 3,3 0 -diaminobenzidine as substrate. The specificity of the antigen detection was always ascertained by omission of the primary antibody binding step.
For intracellular localization in kidney and lung, NDUFAF6 was detected with rabbit polyclonal anti-NDUFAF6 antibody diluted 1:300 in 5% BSA, in PBS. Mitochondrial ATP synthase subunit b (ATP5B) and cytoplasmic located heat shock protein 90 (HSP90) were detected with mouse monoclonal anti-ATP5B antibody (ab14730, Abcam) and anti-Hsp90 antibody (ab 79848, Abcam), respectively, both diluted 1:100 in 5% BSA, in PBS. For fluorescence detection, corresponding species specific secondary antibodies Alexa Fluor 
Electron microscopy
Kidney biopsies were fixed with 3% glutaraldehyde in 0.1 M phosphate buffer, post-fixed with 1% OsO 4 , dehydrated and embedded into Durcupan-Epon mixture. Ultrathin sections were double contrasted with uranyl acetate and lead nitrate and then analyzed using a transmission electron microscope (JEOL 1200 EX).
Isolation of mitochondria
For the analysis of complex I assembly, mitochondria from fibroblast cells were isolated at 4 C by a hypo-osmotic shock method (43) . The freshly harvested cells were disrupted in 10 mM Tris-HCl, pH 7.4, homogenized in a Teflon/glass homogenizer (10% homogenate, w/v) and then sucrose was added to a final concentration of 0.25 M. Mitochondria were sedimented from the 600-g post-nuclear supernatant by 10-min centrifugation at 10 000g, washed and resuspended in 0.25 M sucrose, 2 mM EGTA, 40 mM KCl, 20 mM Tris, pH 7.4.
Electrophoresis, Western-blot analysis, in-gel complex I activity Mitochondrial proteins were solubilized with digitonin at 2 g/g (detergent/protein ratio) for 15 min on ice. The samples were centrifuged for 20 min at 4 C and 30 000g, and Coomassie Brilliant Blue G dye (Serva Blue G-250, 0.125 g/g detergent) and 5% glycerol were added to the supernatants before electrophoresis. Gels were blotted onto a PVDF membrane (Millipore) and the membrane was blocked in 5% defatted milk in TBS (150 mM NaCl, 10 mM Tris, pH 7. . The fluorescence was detected using ODYSSEY infra-red imaging system (Li-Cor Biosciences) and the signal was quantified using Aida 3.21 Image Analyzer software. Complex I activity was detected on native gels immediately after electrophoresis according to (44) . Briefly, gels were incubated in complex I activity assay buffer (2.5 mg/ml nitrotetrazolium blue, 0.1 mg/ml NADH, 5 mM Tris-HCl, pH 7.4) from 1 h to overnight. The gels were transferred to 5 mM Tris-HCl pH 7.4 and scanned.
LFQ protein mass spectrometry analysis
Cell pellets (affected individual versus control NHDFC fibroblasts) corresponding to 100 mg of protein were solubilized using sodium deoxycholate (1% (w/v) final conc.), reduced with TCEP [tris(2-carboxyethyl)phosphine], alkylated with MMTS (Smethyl methanethiosulfonate), digested sequentially with Lys-C and trypsin and extracted with ethylacetate saturated with water as described (45) . Samples were desalted on Empore C18 columns, dried in Speedvac and dissolved in 0.1% TFA + 2% acetonitrile. About 1 mg of peptide digests were separated on 50 cm C18 column using 2.5 h elution gradient and analyzed in a DDA mode on a Orbitrap Fusion Tribrid (Thermo Scientific) mass spectrometer. Resulting raw files were processed in MaxQuant (v. 1.5.3.28) (46) with label-free quantification (LFQ) algorithm MaxLFQ (47) . Downstream analysis and visualization was performed in Perseus (v. 1.5.3.1).
Complementation of fibroblasts with wt cDNA
Affected or control fibroblasts were transfected either with vector containing either the wtNDUFAF6 isoform v_1 cDNA (in the same manner as used for HeLa and HEK293 cells) or the green fluorescent protein (GFP) (used as a control) using Nucleofector device and NHDF nucleofection kit (VPD-1001, Lonza, Switzerland). For each transfection 3Â10 6 cells and 2 lg of DNA was used. Cells were analyzed 5-day post-transfection.
Mitochondrial respiration measurement
Respiration of fibroblasts was measured at 30 C using
Oxygraph-2k (Oroboros, Austria), essentially as described (48) . Briefly, freshly harvested cells were suspended in KCl medium (80 mM KCl, 10 mM Tris-Cl, 3 mM MgCl 2 , 1 mM EDTA, 5 mM potassium phosphate, pH 7.4) and permeabilized with digitonin (0.05 g/g of protein). Substrates and inhibitors were used at the following concentrations: 10 mM pyruvate, 2 mM malate, 1 mM ADP, 10 mM glutamate, 10 mM succinate, 10 mM glycerol 3-phosphate, 500 nM oligomycin, 100-200 nM FCCP, 1 lM rotenone, 10 mM malonate, 1 lM antimycin A, 2 mM ascorbate, 1 mM TMPD, 0.5 mM KCN. Oxygen consumption was expressed in pmol oxygen/s/mg protein.
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